Latest total current liabilities for KRTX: $68M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Karuna Therapeutics (KRTX) currently reports a total current liabilities of $68M as of December 2023. That compares with $34M in the prior-year period — up 100.7% year over year. Use the charts on this page to explore Karuna Therapeutics's total current liabilities history and peer comparisons.
Karuna Therapeutics's total current liabilities increased from $34M to $68M — a 100.7% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Karuna Therapeutics reported $68M in total current liabilities as of December 2023. That compares with $34M in the prior-year period — up 100.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total current liabilities of $68M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Karuna Therapeutics, and consider following KRTX for alerts when major investors trade the stock.
Karuna Therapeutics is classified in the Healthcare sector. On total current liabilities, it currently shows $68M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KRTX with unrelated industries.